<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03757000</url>
  </required_header>
  <id_info>
    <org_study_id>YY-20394-001</org_study_id>
    <nct_id>NCT03757000</nct_id>
  </id_info>
  <brief_title>A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies</brief_title>
  <official_title>A Phase I Study of YY-20394 Given Orally to Patients With Relapsed or Refractory B Cell Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai YingLi Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai YingLi Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol YY-20394-001 is a phase I open-label, first in human, dose escalation study to&#xD;
      assess the tolerability, pharmacokinetics (PK) and efficacy of YY-20394 in patients with&#xD;
      relapse or refractory B cell malignant hematological tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part study comprised of a dose escalation part and a dose expansion part.&#xD;
&#xD;
      In the dose escalation part single patient cohorts will be dosed until a single related&#xD;
      toxicity of Grade ≥ 3 or a Dose Limiting Toxicity (DLT) is observed. If this occurs, the&#xD;
      study will switch to a conventional oncology 3+3 design (3 patients per dose cohort, with the&#xD;
      potential to add an additional 3 patients if toxicity is observed) and escalation will&#xD;
      continue until the maximum tolerated dose (MTD) is reached and a recommended Phase II (RP2D)&#xD;
      dose is determined. Once the MTD is established a separate dose expansion part will enroll up&#xD;
      total additional 12 patients at the RP2D.&#xD;
&#xD;
      In this clinical trial, YY-20394 is given orally once daily. A treatment cycle is defined as&#xD;
      28 days. YY-20394 was given until disease progression, unacceptable toxicity, or withdrawal&#xD;
      from the study. The protocol was initiated with a single-patient cohort, treated with oral&#xD;
      YY-20394 20 mg once daily (QD). Subsequent cohorts used a 3+3 design and evaluated doses of&#xD;
      40-320mg QD. Adverse events (AEs) were graded by NCI-CTCAE v4.0. Efficacy was assessed&#xD;
      according to IWG-NHL and CLL consensus response criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 25, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limited toxicities evaluated with NCI-CTC AE v4.0</measure>
    <time_frame>within 28 days after the first dose</time_frame>
    <description>Incidence of dose limited toxicities and associated dose of YY-20394</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events evaluated by NCI CTCAE v4.0</measure>
    <time_frame>from the first dose to within 30 days after the last dose</time_frame>
    <description>Incidence of adverse events and associated dose of YY-20394</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of YY-20394</measure>
    <time_frame>within 56 days after the first dose</time_frame>
    <description>This composite endpoint will measure the plasma concentration of YY-20394.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>within 30 days after the last dose</time_frame>
    <description>the proportion of subjects who have a Complete Response or Partial Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>within 30 days after the last dose</time_frame>
    <description>the proportion of subjects who have a Complete Response or Partial Response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>B-cell Lymphoma Recurrent</condition>
  <condition>B-cell Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>YY-20394</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).&#xD;
YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY-20394</intervention_name>
    <description>YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (&gt;1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.</description>
    <arm_group_label>YY-20394</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and/or females over age 18&#xD;
&#xD;
          2. Histologically or cytologically confirmed B cell malignancies&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group performance status of 0 to 2&#xD;
&#xD;
          4. Life expectancy of at least 3 months&#xD;
&#xD;
          5. At least one measurable lesion by Computed Tomography(CT) or Magnetic Resonance&#xD;
             Imaging(MRI) according to, which is not in irradiated area (only for expansion phase)&#xD;
&#xD;
          6. Acceptable hematologic status:&#xD;
&#xD;
             Absolute neutrophil count(ANC)≥1.0×109/L; Platelet count(PLT)≥70×109/L;&#xD;
             Hemoglobin(Hb)≥80 g/L; Total bilirubin(TBIL)≤1.5×Upper limit of normal value(ULN);&#xD;
             Alanine aminotransferase(ALT)≤1.5×ULN; Aspartate aminotransferase(AST)≤1.5×ULN; Blood&#xD;
             urea nitrogen(BUN)≤1×ULN; Creatinine(Cr)≤1×ULN; Left Ventricular Ejection&#xD;
             Fractions(LVEF)≥50%； QTcF：male&lt;450 ms,female&lt;470 ms&#xD;
&#xD;
          7. The washout period from the last time accepting any anti-tumor treatment (including&#xD;
             radiation therapy, chemotherapy, hormone therapy, surgery, or molecular targeted&#xD;
             therapy) to participating in this test should be 4 weeks or more.&#xD;
&#xD;
          8. The last time participate in an investigational drug or device study should be more&#xD;
             than one month prior to study entry.&#xD;
&#xD;
          9. Ability to understand the purposes and risks of the study&#xD;
&#xD;
         10. Availability of the signed informed consent forms (ICFs) approved by the&#xD;
             investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC) of&#xD;
             the study site obtained before entering the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously treated with PI3Kδ inhibitors and cause disease progression.&#xD;
&#xD;
          2. Any anti-tumor treatment, within 4 weeks prior to study entry.&#xD;
&#xD;
          3. There are third interstitial effusions (such as massive pleural effusion and ascites)&#xD;
             which can not be controlled by drainage or other methods.&#xD;
&#xD;
          4. The dosage of steroid hormone (prednisone equivalent) was greater than 20mg/ days, and&#xD;
             lasted for more than 14 days.&#xD;
&#xD;
          5. Medical history of difficulty in swallowing, malabsorption, or other chronic&#xD;
             gastrointestinal disease, or conditions that may hamper compliance and/or absorption&#xD;
             of the tested product.&#xD;
&#xD;
          6. During the study period, drugs that may prolong the QT (such as anti arrhythmic drugs)&#xD;
             could not be interrupted.&#xD;
&#xD;
          7. Patients with central nervous system (CNS) involvement.&#xD;
&#xD;
          8. Allergy, or known to be allergic to the drug.&#xD;
&#xD;
          9. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy(such as pneumonia).&#xD;
&#xD;
         10. Known infection with human immunodeficiency virus (HIV), hepatitis B virus(HBV), or&#xD;
             hepatitis C virus (HCV).&#xD;
&#xD;
         11. History of immunodeficiency, including HIV positive test, other acquired or congenital&#xD;
             immunodeficiency disorders, organ transplantation or allogeneic bone marrow&#xD;
             transplantation.&#xD;
&#xD;
         12. Autologous hematopoietic stem cell transplantation was received within 90 days before&#xD;
             the first dose treatment.&#xD;
&#xD;
         13. Has suffered from any heart disease, including: (1) angina pectoris; (2) medicated or&#xD;
             clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5)&#xD;
             any other heart disease judged by the researchers not suitable for the test.&#xD;
&#xD;
         14. The baseline pregnancy test was positive in pregnant women, lactating women or fertile&#xD;
             women.&#xD;
&#xD;
         15. According to the judgement of the researcher, there are concomitant diseases that&#xD;
             seriously endanger the safety of patients or affect the completion of the study (such&#xD;
             as severe hypertension, diabetes, thyroid diseases, etc.).&#xD;
&#xD;
         16. Receiving granulocyte colony-stimulating factor(GCSF) or blood transfusion within 7&#xD;
             days before screening.&#xD;
&#xD;
         17. Patients suffering from other primary malignant tumors in the past 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanying Bao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai YingLi Pharmaceutical Co. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanying Bao, MD,PhD</last_name>
    <phone>86 21-51370693</phone>
    <email>hybao@yl-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuanyuan Xu, M.S.</last_name>
    <phone>86 21-51320088</phone>
    <phone_ext>8588</phone_ext>
    <email>yyxu@yl-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuqin Song, MD,PhD</last_name>
      <phone>86 10-88140650</phone>
      <email>songyuqin622@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Meifeng Tu, MD,PhD</last_name>
      <phone>86 10-88121122</phone>
      <email>44329472@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yuqin Song, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meifeng Tu, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lingyan Ping, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiangyong Li, MD,PhD</last_name>
      <phone>86 25-83714511</phone>
      <email>lijianyonglm@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Xu, MD,PhD</last_name>
      <phone>86 25-83714511</phone>
      <email>xuwei0484@jsph.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jianyong Li, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meifeng Tu, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lugui Qiu, MD,PhD</last_name>
      <phone>86 22-23909172</phone>
      <email>qiulg@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Junyuan Qi, MD,PhD</last_name>
      <phone>86 22-23909999</phone>
      <email>qijy@ihcams.ac.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Lugui Qiu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junyuan Qi, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.wanfangdata.com.cn/details/detail.do?_type=conference&amp;id=7408347</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.wanfangdata.com.cn/details/detail.do?_type=perio&amp;id=ez200803022</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Eisenreich A, Rauch U. PI3K inhibitors in cardiovascular disease. Cardiovasc Ther. 2011 Feb;29(1):29-36. doi: 10.1111/j.1755-5922.2010.00206.x.</citation>
    <PMID>20626398</PMID>
  </results_reference>
  <results_reference>
    <citation>Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004 Apr 23;304(5670):554. doi: 10.1126/science.1096502. Epub 2004 Mar 11. No abstract available.</citation>
    <PMID>15016963</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008 Sep 18;27(41):5497-510. doi: 10.1038/onc.2008.245.</citation>
    <PMID>18794884</PMID>
  </results_reference>
  <results_reference>
    <citation>Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 2008 Sep;99(9):1734-40. doi: 10.1111/j.1349-7006.2008.00891.x. Epub 2008 Jul 4.</citation>
    <PMID>18616528</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.</citation>
    <PMID>24615777</PMID>
  </results_reference>
  <results_reference>
    <citation>Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29;123(22):3406-13. doi: 10.1182/blood-2013-11-538546. Epub 2014 Mar 10.</citation>
    <PMID>24615776</PMID>
  </results_reference>
  <results_reference>
    <citation>Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.</citation>
    <PMID>24450858</PMID>
  </results_reference>
  <results_reference>
    <citation>Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22.</citation>
    <PMID>24450857</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>December 6, 2018</last_update_submitted>
  <last_update_submitted_qc>December 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YY-20394</keyword>
  <keyword>B-cell Lymphoma Recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03757000
org study id: YY-20394-001
nct id: NCT03757000
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Protocol YY-20394-001 is a phase I open-label, first in human, dose escalation study to
      assess the tolerability, pharmacokinetics (PK) and efficacy of YY-20394 in patients with
      relapse or refractory B cell malignant hematological tumor.
This is a two-part study comprised of a dose escalation part and a dose expansion part.

      In the dose escalation part single patient cohorts will be dosed until a single related
      toxicity of Grade ≥ 3 or a Dose Limiting Toxicity (DLT) is observed. If this occurs, the
      study will switch to a conventional oncology 3+3 design (3 patients per dose cohort, with the
      potential to add an additional 3 patients if toxicity is observed) and escalation will
      continue until the maximum tolerated dose (MTD) is reached and a recommended Phase II (RP2D)
      dose is determined. Once the MTD is established a separate dose expansion part will enroll up
      total additional 12 patients at the RP2D.

      In this clinical trial, YY-20394 is given orally once daily. A treatment cycle is defined as
      28 days. YY-20394 was given until disease progression, unacceptable toxicity, or withdrawal
      from the study. The protocol was initiated with a single-patient cohort, treated with oral
      YY-20394 20 mg once daily (QD). Subsequent cohorts used a 3+3 design and evaluated doses of
      40-320mg QD. Adverse events (AEs) were graded by NCI-CTCAE v4.0. Efficacy was assessed
      according to IWG-NHL and CLL consensus response criteria.
allocation: N/A
intervention model: Single Group Assignment
intervention model description: dose escalation
primary purpose: Treatment
masking: None (Open Label)
measure: Dose limited toxicities evaluated with NCI-CTC AE v4.0
time frame: within 28 days after the first dose
description: Incidence of dose limited toxicities and associated dose of YY-20394
measure: Adverse events evaluated by NCI CTCAE v4.0
time frame: from the first dose to within 30 days after the last dose
description: Incidence of adverse events and associated dose of YY-20394
measure: Plasma concentration of YY-20394
time frame: within 56 days after the first dose
description: This composite endpoint will measure the plasma concentration of YY-20394.
measure: Objective response rate
time frame: within 30 days after the last dose
description: the proportion of subjects who have a Complete Response or Partial Response
measure: Disease control rate
time frame: within 30 days after the last dose
description: the proportion of subjects who have a Complete Response or Partial Response
arm group label: YY-20394
arm group type: Experimental
description: YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).
YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day.
intervention type: Drug
intervention name: YY-20394
description: YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
arm group label: YY-20394
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Hanying Bao, PhD
role: Study Director
affiliation: Shanghai YingLi Pharmaceutical Co. Ltd.
last name: Hanying Bao, MD,PhD
phone: 86 21-51370693
email: hybao@yl-pharma.com
last name: Yuanyuan Xu, M.S.
phone: 86 21-51320088
phone ext: 8588
email: yyxu@yl-pharma.com
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
investigator: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
contact backup: 
investigator: 
investigator: 
facility: 
status: Recruiting
contact: 
contact backup: 
investigator: 
investigator: 
country: China
url: http://www.wanfangdata.com.cn/details/detail.do?_type=conference&id=7408347
description: Related Info
url: http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=ez200803022
description: Related Info
citation: Eisenreich A, Rauch U. PI3K inhibitors in cardiovascular disease. Cardiovasc Ther. 2011 Feb;29(1):29-36. doi: 10.1111/j.1755-5922.2010.00206.x.
PMID: 20626398
citation: Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004 Apr 23;304(5670):554. doi: 10.1126/science.1096502. Epub 2004 Mar 11. No abstract available.
PMID: 15016963
citation: Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008 Sep 18;27(41):5497-510. doi: 10.1038/onc.2008.245.
PMID: 18794884
citation: Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 2008 Sep;99(9):1734-40. doi: 10.1111/j.1349-7006.2008.00891.x. Epub 2008 Jul 4.
PMID: 18616528
citation: Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.
PMID: 24615777
citation: Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014 May 29;123(22):3406-13. doi: 10.1182/blood-2013-11-538546. Epub 2014 Mar 10.
PMID: 24615776
citation: Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.
PMID: 24450858
citation: Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22.
PMID: 24450857
responsible party type: Sponsor
mesh term: Lymphoma, B-Cell
mesh term: Leukemia, Lymphocytic, Chronic, B-Cell
mesh term: Hematologic Neoplasms
sharing ipd: Undecided